Claims
- 1. A pharamceutical composition in tablet form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of 10-ethyl-10-deazaminopterin per tablet therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic carrier or diluent therefor.
- 2. A pharmaceutical composition according to claim 1 in which the 10-ethyl-10-deazaminopterin is in the form of a pharmaceutically acceptable acid addition salt or quaternary ammonium derivative.
- 3. A pharmaceutical composition in capsule form for treating leukemia or an ascites tumor comprising an amount within the range from 0.1 to about 500 mg of 10-ethyl-10-deazaminopterin per capsule therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic inert carrier or diluent therefor.
- 4. A pharmaceutical composition according to claim 3 in which the 10-ethyl-10-deazaminopterin is in the form of a pharmaceutically acceptable acid addition salt or quaternary ammonium derivative.
- 5. A pharmaceutical composition in suppository form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of 10-ethyl-10-deazaminopterin per suppository therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic inert carrier or diluent therefor.
- 6. A pharmaceutical composition according to claim 5 in which the 10-ethyl-10-deazaminopterin is in the form of a pharmaceutically acceptable acid addition salt or quaternary ammonium derivative.
- 7. A pharmaceutical composition in cachet form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of a 10-ethyl-10-deazaminopterin per cachet therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic inert carrier or diluent therefor.
- 8. A pharmaceutical composition according to claim 7 in which the 10-ethyl-10-deazaminopterin is in the form of a pharmaceutically acceptable acid addition salt or quaternary ammonium derivative.
- 9. A pharmaceutical composition in sterile aqueous form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of 10-ethyl-10-deazaminopterin therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic sterile inert aqueous carrier or diluent therefor.
- 10. A pharmaceutical composition according to claim 9 in which the 10-ethyl-10-deazaminopterin is in the form of a pharmaceutically acceptable acid addition salt or quaternary ammonium derivative.
- 11. A pharmaceutical composition according to claim 9 in aqueous solution form.
- 12. A pharmaceutical composition according to claim 9 in aqueous dispersion form.
- 13. A process for treating leukemia and ascites tumors which comprises administering to a warm-blooded animal having an abnormal proportion of leukocytes or other evidence of the malignancy, a therapeutic and relatively nontoxic amount of 10-ethyl-10-deazaminopterin.
- 14. A process according to claim 13 in which the 10-ethyl-10-deazaminopterin is administered as a pharmaceutically acceptable salt thereof.
- 15. A process according to claim 13 in which the 10-ethyl-10-deazaminopterin is administered in an amount within the range from about 0.1 to about 500 mg per day.
- 16. A process according to claim 13 in which the 10-ethyl-10-deazaminopterin is administered with an inert diluent or carrier.
- 17. A process according to claim 13 in which the 10-ethyl-10-deazaminopterin is administered orally.
- 18. A process according to claim 13 in which the 10-ethyl-10-deazaminopterin is administered parenterally.
Parent Case Info
This is a continuation of application Ser. No. 808,579, filed Dec. 13, 1985, now abandoned, which in turn is a continuation of Ser. No. 754,370, filed July 11, 1985, now abandoned, which in turn is a continuation of Ser. No. 701,885, filed Feb. 15, 1985, now abandoned, which in turn is a continuation of Ser. No. 645,387, filed Aug. 29, 1984, now abandoned, which in turn is a continuation of Ser. No. 513,254, filed July 12, 1983, now abandoned, which in turn is a continuation of Ser. No. 397,274, filed July 12, 1982, now abandoned, which in turn is a continuation of Ser. No. 75,913, filed Sept. 17, 1979, now U.S. Pat. No. 4,393,064, patented July 12, 1983, which in turn is a continuation-in-part of Ser. No. 883,627, filed Mar. 6, 1978, of Ser. No. 761,152, filed Jan. 21, 1977, and of Ser. No. 664,213, filed Mar. 5, 1976, all three now abandoned.
ORIGIN OF INVENTION
The invention described herein was in part made in the course of work under a grant or award from the National Institute of Health, Department of Health, Education and Welfare.
Non-Patent Literature Citations (1)
Entry |
Degraw et al., J. of Med. Chem., 1974, vol. 17, No. I, pp. 552-553. |
Related Publications (2)
|
Number |
Date |
Country |
|
761152 |
Jan 1977 |
|
|
664213 |
Mar 1976 |
|
Continuations (7)
|
Number |
Date |
Country |
Parent |
808579 |
Dec 1985 |
|
Parent |
754370 |
Jul 1985 |
|
Parent |
701885 |
Feb 1985 |
|
Parent |
645387 |
Aug 1984 |
|
Parent |
513254 |
Jul 1983 |
|
Parent |
397274 |
Jul 1982 |
|
Parent |
75913 |
Sep 1979 |
|